APA (7th ed.) Citation

H, S., H, M., S, S., N, T., CM, S., A, R., . . . I, V. (2025). Inhibition of the NLRP3 inflammasome using MCC950 reduces vincristine-induced adverse effects in an acute lymphoblastic leukemia patient-derived xenograft model. HemaSphere, 9(3), e70092. https://doi.org/10.1002/hem3.70092

Chicago Style (17th ed.) Citation

H, Starobova, McCalmont H, Shatunova S, Tay N, Smith CM, Robertson A, Winkler I, Lock RB, and Vetter I. "Inhibition of the NLRP3 Inflammasome Using MCC950 Reduces Vincristine-induced Adverse Effects in an Acute Lymphoblastic Leukemia Patient-derived Xenograft Model." HemaSphere 9, no. 3 (2025): e70092. https://doi.org/10.1002/hem3.70092.

MLA (9th ed.) Citation

H, Starobova, et al. "Inhibition of the NLRP3 Inflammasome Using MCC950 Reduces Vincristine-induced Adverse Effects in an Acute Lymphoblastic Leukemia Patient-derived Xenograft Model." HemaSphere, vol. 9, no. 3, 2025, p. e70092, https://doi.org/10.1002/hem3.70092.